Skip to main content

Table 6 Analysis of factors related to bleeding

From: Safety profile of bivalirudin in Chinese female patients undergoing percutaneous coronary intervention: a multi-center study

Items

Bleeding

Univariate

Multivariate

No (%)

Yes (%)

P value

OR (95% CI)

P value

OR (95% CI)

Age

  

0.273

 

–

 

  > 75 years

226 (97.8)

5 (2.2)

 

1.878 (0.608–5.798)

 

–

  ≤ 75 years

679 (98.8)

8 (1.2)

 

Reference

 

–

BMI

  

0.997

 

–

 

  > 28 kg/m2

87 (100.0)

0 (0.0)

 

–

 

–

  ≤ 28 kg/m2

760 (98.3)

13 (1.7)

 

–

 

–

History of diabetes mellitus

  

0.005

 

0.007

 

 Yes

266 (96.7)

9 (3.3)

 

5.405 (1.650–17.704)

 

5.227 (1.562–17.495)

 No

639 (99.4)

4 (0.6)

 

Reference

 

Reference

History of allergy

  

0.654

 

–

 

 Yes

103 (98.1)

2 (1.9)

 

1.416 (0.309–6.476)

 

–

 No

802 (98.6)

11 (1.4)

 

Reference

 

–

History of cardiac surgery

  

0.984

 

–

 

 Yes

71 (98.6)

1 (1.4)

 

0.979 (0.125–7.637)

 

–

 No

834 (98.6)

12 (1.4)

 

Reference

 

–

History of renal function impairment

  

0.328

 

–

 

 Yes

26 (96.3)

1 (3.7)

 

2.817 (0.353–22.482)

 

–

 No

879 (98.7)

12 (1.3)

 

Reference

 

–

History of critical respiratory disease

  

0.998

 

–

 

 Yes

20 (100.0)

0 (0.0)

 

–

 

–

 No

885 (98.6)

13 (1.4)

 

–

 

–

Clinical presentation-UA

  

0.048

 

0.103

 

 Yes

359 (99.7)

1 (0.3)

 

0.127 (0.016–0.979)

 

0.178 (0.022–1.420)

 No

546 (97.8)

12 (2.2)

 

Reference

 

Reference

Clinical presentation-STEMI

  

0.182

 

–

 

 Yes

322 (97.9)

7 (2.1)

 

2.112 (0.704–6.339)

 

–

 No

583 (99.0)

6 (1.0)

 

Reference

 

–

Clinical presentation-NSTMI

  

0.889

 

–

 

 Yes

127 (98.4)

2 (1.6)

 

1.114 (0.244–5.084)

 

–

 No

778 (98.6)

11 (1.4)

 

Reference

 

–

Clinical presentation-SCAD

  

0.164

 

–

 

 Yes

96 (97.0)

3 (3.0)

 

2.528 (0.684–9.346)

 

–

 No

809 (98.8)

10 (1.2)

 

Reference

 

–

CRUSADE risk stratification

  

0.003

 

0.016

 

 High risk

239 (96.4)

9 (3.6)

 

6.129 (1.870–20.087)

 

4.475 (1.323–15.134)

 No high risk

651 (99.4)

4 (0.6)

 

Reference

 

Reference

Operative timing

  

0.090

 

–

 

 Elective operation

564 (99.1)

5 (0.9)

 

0.378 (0.123–1.164)

 

–

 Emergency operation

341 (97.7)

8 (2.3)

 

Reference

 

–

Types of coronary interventional therapy

  

0.658

 

–

 

 Stent implantation

860 (98.6)

12 (1.4)

 

0.628 (0.080–4.936)

 

–

 Others

45 (97.8)

1 (2.2)

 

Reference

 

–

Types of stents

  

0.999

 

–

 

 Drug stent

848 (98.6)

12 (1.4)

 

–

 

–

 Others

15 (100.0)

0 (0.0)

 

–

 

–

Arterial access

  

0.997

 

–

 

 Radial artery

835 (98.5)

13 (1.5)

 

–

 

–

 Others

70 (100.0)

0 (0.0)

 

–

 

–

Culprit vessel

  

0.559

 

–

 

 Multiple

201 (99.0)

2 (1.0)

 

0.637 (0.140–2.896)

 

–

 Single

704 (98.5)

11 (1.5)

 

Reference

 

–

Administration of bivalirudin-preoperative or intraoperative

  

0.401

 

–

 

 Yes

30 (96.8)

1 (3.2)

 

2.431 (0.306–19.304)

 

–

 No

875 (98.6)

12 (1.4)

 

Reference

 

–

Administration of bivalirudin-postoperative ≤ 4 h

  

0.126

 

–

 

 Yes

770 (98.8)

9 (1.2)

 

0.394 (0.120–1.299)

 

–

 No

135 (97.1)

4 (2.9)

 

Reference

 

–

Administration of bivalirudin-postoperative > 4 h

  

0.215

 

–

 

 Yes

105 (97.2)

3 (2.8)

 

2.286 (0.619–8.439)

 

–

 No

800 (98.8)

10 (1.2)

 

Reference

 

–

Combined with GP IIb/IIIa inhibitors

  

0.326

 

–

 

 Yes

652 (98.3)

11 (1.7)

 

2.134 (0.470–9.696)

 

–

 No

253 (99.2)

2 (0.8)

 

Reference

 

–

TIMI flow grade (pre-procedure)

  

0.173

 

–

 

 2–3

518 (98.1)

10 (1.9)

 

2.465 (0.674–9.016)

 

–

 0–1

383 (99.2)

3 (0.8)

 

Reference

 

–

TIMI flow grade (post-procedure)

  

0.033

 

0.069

 

 2–3

897 (98.7)

12 (1.3)

 

0.094 (0.011–0.821)

 

0.105 (0.009–1.187)

 0–1

7 (87.5)

1 (12.5)

 

Reference

 

Reference

  1. Bold value means statistically significant
  2. OR, odds ratio; CI, confidence interval; BMI, body mass indexes; UA, unstable angina; STEMI, ST-segment elevation myocardial infarction; NSTMI, non-ST-segment elevation myocardial infarction; SCAD, spontaneous coronary artery dissection; CRUSADE, Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines; GP, glycoprotein; TIMI, thrombolysis in myocardial infarction